Journal of Blood Transfusion / 2016 / Article / Tab 3

Research Article

Mitigating the Risk of Transfusion-Transmitted Dengue in Australia

Table 3

Dengue endemicity and approaches used by blood operators for managing TT-DENV risk. Adapted from Teo et al., 2009 [31].

CountryEndemicityManagement approach

AustraliaNonendemic/episodic outbreaks in Queensland [6, 8](i) 4-week deferral for history of dengue infection [16]
(ii) 4-week deferral for persons returning from dengue affected areas [16]
CanadaNonendemic3-week travel-related deferral for travel outside of Canada, continental USA, or Europe [32]
Hong KongNonendemic [33](i) 6-month deferral for history of dengue infection [31]
(ii) 2-week deferral for history of fever [31]
(iii) No travel-related deferral for dengue [31]
NetherlandsNonendemic(i) 2-week deferral for history of dengue infection [34]
(ii) 2-week deferral for history of fever [34]
(iii) 4-week travel-related deferral for donors returning from dengue risk areas [34]
New ZealandNonendemic(i) 4-week deferral for history of dengue infection [35]
(ii) No travel-related deferral for dengue [35]
Puerto RicoEndemic [36]Pathogen inactivation (Intercept) recently implemented for use on plasma and platelet products [37]
SingaporeEndemic [38](i) 6-month deferral for history of dengue infection [31]
(ii) 3-week deferral for history of fever [31]
(iii) No travel-related deferral for dengue [31]
Sri LankaEndemic [39](i) No specific deferral for history of dengue infection [31]
(ii) 2-week deferral for history of fever [31]
(iii) No travel-related deferral for dengue [31]
United KingdomNonendemic(i) 2-week deferral for history of dengue infection [31]
(ii) No travel-related deferral for dengue [31]
United States of AmericaNonendemic/episodic outbreaks in some states [8, 40](i) 4-week deferral for history of dengue infection [31]
(ii) No travel-related deferral for dengue [31]